Top Markets
#1 ALEO ALEO +7.58%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +5.79%
#3 TDCCP TDCCP +4.33%
#4 Cortex Cortex +4.27%
#5 Synapse Synapse +4.24%
#6 Steem Steem +3.89%
#7 MANTRA MANTRA +3.47%
#8 Moo Deng Moo Deng +3.47%
#9 Zilliqa Zilliqa +3.30%
#10 Ontology Gas Ontology Gas +3.07%
Coin of the day
ALEO ALEO
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rang in aandelen #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Aandeelprijs
$0.04443294
Marktkapitalisatie
$13.65M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-32.53%
Land
AU
Handel Noxopharm Limited (NOX)

Categorie

Healthcare
EPS voor Noxopharm Limited (NOX)
EPS per June 2026 TTM: $-0.01
Volgens de laatste financiële rapporten en de aandelenkoers van Noxopharm Limited is de huidige EPS van het bedrijf (TTM) $-0.01. Eind 2024 had het bedrijf een EPS van $-0.01, een daling ten opzichte van de EPS van 2023 die $-0.03 bedroeg.
EPS-geschiedenis van Noxopharm Limited van 2016 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
2026 (TTM) $-0.01 8.00%
2025 $-0.01 35.80%
2024 $-0.01 -76.38%
2023 $-0.03 -22.40%
2022 $-0.04 66.79%
2021 $-0.03 1,792.86%
2020 0.00 -97.54%
2019 $-0.06 -48.69%
2018 $-0.11 314.55%
2017 $-0.03 66.46%
2016 $-0.02 0.00%
EPS van vergelijkbare bedrijven of concurrenten
Bedrijf EPS EPS-verschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -160,470.37%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 73,788.89%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 48,881.48%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -256,951.85%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH